CN118726256A - 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 - Google Patents

使用羟基柠檬酸和/或其盐产生t细胞群体的方法 Download PDF

Info

Publication number
CN118726256A
CN118726256A CN202410809055.0A CN202410809055A CN118726256A CN 118726256 A CN118726256 A CN 118726256A CN 202410809055 A CN202410809055 A CN 202410809055A CN 118726256 A CN118726256 A CN 118726256A
Authority
CN
China
Prior art keywords
cells
hydroxycitrate
salt
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410809055.0A
Other languages
English (en)
Chinese (zh)
Inventor
苏曼·库玛·沃德纳拉
尼古拉斯·P·雷斯蒂福
里吉尔·J·基斯顿
罗伯特·L·艾尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN118726256A publication Critical patent/CN118726256A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202410809055.0A 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 Pending CN118726256A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862661941P 2018-04-24 2018-04-24
US62/661,941 2018-04-24
CN201980037634.5A CN112262212B (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
PCT/US2019/028513 WO2019209715A1 (en) 2018-04-24 2019-04-22 Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980037634.5A Division CN112262212B (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法

Publications (1)

Publication Number Publication Date
CN118726256A true CN118726256A (zh) 2024-10-01

Family

ID=66641471

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410809055.0A Pending CN118726256A (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
CN201980037634.5A Active CN112262212B (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980037634.5A Active CN112262212B (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法

Country Status (7)

Country Link
US (2) US12415845B2 (https=)
EP (1) EP3784774B1 (https=)
JP (1) JP7342030B2 (https=)
CN (2) CN118726256A (https=)
AU (1) AU2019260656B2 (https=)
CA (1) CA3097858A1 (https=)
WO (1) WO2019209715A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004028A (ko) * 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 동종 car t 세포를 제조하는 방법
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022011129A1 (en) * 2020-07-09 2022-01-13 The Board Of Trustees Of The Leland Stanford University Multi-parallel analysis of t-cell therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP2694549B1 (en) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
JP6378172B2 (ja) 2012-05-22 2018-08-22 アメリカ合衆国 マウス抗ｎｙ−ｅｓｏ−１ｔ細胞受容体
IL286786B (en) 2012-09-14 2022-09-01 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst T cell receptors that recognize mhc mage–a3 are restricted type ii
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
AU2015209263A1 (en) 2014-01-24 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-NY-BR-1 polypeptides, proteins, and chimeric antigen receptors
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
AU2014407539B2 (en) 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
JPWO2016067968A1 (ja) * 2014-10-29 2017-04-27 昭和電工株式会社 ミトコンドリア機能改善剤
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
US20190321314A1 (en) 2016-09-15 2019-10-24 Memorial Sloan Kettering Cancer Center Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders

Also Published As

Publication number Publication date
JP2021521828A (ja) 2021-08-30
US12415845B2 (en) 2025-09-16
CN112262212A (zh) 2021-01-22
AU2019260656A2 (en) 2020-12-17
JP7342030B2 (ja) 2023-09-11
AU2019260656A1 (en) 2020-12-10
CA3097858A1 (en) 2019-10-31
EP3784774A1 (en) 2021-03-03
WO2019209715A1 (en) 2019-10-31
CN112262212B (zh) 2024-07-12
EP3784774C0 (en) 2025-11-19
US20210071141A1 (en) 2021-03-11
EP3784774B1 (en) 2025-11-19
AU2019260656B2 (en) 2025-08-21
US20260042814A1 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
US11123369B2 (en) Bispecific CAR T-cells for solid tumor targeting
US11896616B2 (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP6203705B2 (ja) 細胞免疫療法のための方法および組成物
US20260042814A1 (en) Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
ES2907581T3 (es) Método mejorado para la generación de células genéticamente modificadas
CN108473956B (zh) 增强外源性施用t细胞的体内持久性和功效的方法、基因修饰的t细胞和方法以及使用方法
CN113194715B (zh) 用于治疗癌症的材料和方法
JP7747724B2 (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
CN117295515A (zh) 用于癌症免疫治疗的嵌合抗原受体修饰的粒细胞-巨噬细胞祖细胞
TW202102667A (zh) 用於擴增和分化供過繼性細胞治療之ｔ淋巴細胞和天然殺手（ｎｋ）細胞之方法
Peters et al. RNA-encoded interleukin 2 with extended bioavailability amplifies RNA vaccine–induced antitumor T-cell immunity
US20230036952A1 (en) Methods of producing t cell populations using induced pluripotent stem cells
US20250228939A1 (en) Enhanced immune cell therapy
US20230303643A1 (en) Constitutively active tcf1 to promote memory-associated traits in car t cells
Di-Trani Tailoring the bioactivities of IL-12 for cancer immunotherapy with mRNA-based technology: from immunocytokines to armored T cell transfer
WO2025054946A1 (zh) 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
CN121398840A (zh) 共受体嵌合抗原受体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination